老年血管性疾病的普适综合干预方案的研究

注册号:

Registration number:

ChiCTR2300078994 

最近更新日期:

Date of Last Refreshed on:

2023-12-22 11:17:15 

注册时间:

Date of Registration:

2023-12-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

老年血管性疾病的普适综合干预方案的研究

Public title:

Study on a universal comprehensive intervention program for vascular diseases in the elderly

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年血管性疾病的普适综合干预方案的研究

Scientific title:

Study on a universal comprehensive intervention program for vascular diseases in the elderly

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴雪萍 

研究负责人:

曹丰 

Applicant:

Wu Xueping 

Study leader:

Feng Cao 

申请注册联系人电话:

Applicant telephone:

+86 182 1109 2850

研究负责人电话:

Study leader's
telephone:

+86 139 1179 8280

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wuxueping2002@aliyun.com

研究负责人电子邮件:

Study leader's E-mail:

caofeng8828@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区复兴路28号解放军总医院第二临床医学中心心内科

研究负责人通讯地址:

北京市海淀区复兴路28号解放军总医院及国家老年疾病临床研究中心

Applicant address:

Chinese PLA gengeral Hospital

Study leader's address:

National Clinical Reasearch Center for Geriatric Diseases, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

解放军总医院

Applicant's institution:

Chinese PLA gengeral Hospital

研究负责人所在单位:

解放军总医院及国家老年疾病临床研究中心ZHOU

Affiliation of the Leader:

Chinese PLA gengeral Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审第S2023-363-01号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军总医院伦理委员会

Name of the ethic committee:

Ethics Committee of Chinese PLA General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-08-29 00:00:00

伦理委员会联系人:

曹江

Contact Name of the ethic committee:

Caojiang

伦理委员会联系地址:

北京市海淀区复兴路28号解放军总医院

Contact Address of the ethic committee:

28 Fuxing Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6693 7166

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

解放军总医院及国家老年疾病临床研究中心

Primary sponsor:

National Clinical Reasearch Center for Geriatric Diseases, Chinese PLA General Hospital

研究实施负责(组长)单位地址:

北京市海淀区复兴路28号解放军总医院及国家老年疾病临床研究中心

Primary sponsor's address:

National Clinical Reasearch Center for Geriatric Diseases, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军总医院

具体地址:

北京市海淀区复兴路28号解放军总医院国家老年疾病临床研究中心

Institution
hospital:

PLA General Hospital

Address:

National Clinical Research Center for Geriatric Diseases, PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing

经费或物资来源:

科技部

Source(s) of funding:

Ministry of Science and Technology of PRC

研究疾病:

动脉粥样硬化性心脑血管疾病  

Target disease:

Atherosclerotic Cardiovascular Disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确运动及膳食综合干预对延缓血管老化的作用及可能机制  

Objectives of Study:

To clarify the effect and possible mechanism of exercise and dietary combined intervention on delaying vascular aging

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.依从性较差无法按时随访者 2.符合以下任何一条: a)严重心律失常、中、重度瓣膜疾病、房颤、主动脉夹层或动脉瘤、梗阻型肥厚性心肌病、美国纽约心脏病学会(NYHA)心功能分级≥Ⅲ级者 b)患有精神疾病、认知功能不全、视觉障碍或听觉障碍等无法配合者 c)慢性阻塞性肺疾病、活动性肺结核、肺纤维化等慢性肺疾病 d)严重的肝、肾、肺和胸部疾病及血液系统疾病、癌症等慢性消耗性疾病者 e)颈动脉狭窄≥50%,或随机分组前3个月有卒中或短暂性脑缺血发作 f)大动脉炎或免疫性血管炎史 g)处于各种疾病急性期或临床症状不稳定的患者 h)神经、肌肉、骨骼疾病,无法正常运动的患者 i)运动耐力测试期间出现严重不良反应或明显心电图改变等 3.其他任何研究者认为不适宜参与本研究的情况。

Exclusion criteria:

1. Poor compliance and failure to follow up on time 2. Meet any of the following items: A) Patients with severe arrhythmia, moderate or severe valvular disease, atrial fibrillation, aortic dissection or aneurysm, obstructive hypertrophic cardiomyopathy, and the New York Society of Cardiology (NYHA) ≥Ⅲ;B) with mental illness, cognitive insufficiency, visual dysfunction, or auditory impairment who cannot cooperate exercise C) Chronic obstructive pulmonary disease, active pulmonary tuberculosis, pulmonary fibrosis and other chronic pulmonary diseases D) Serious liver, kidney, lung and chest diseases and chronic consumptive diseases such as blood system diseases and cancer E) ≥50% stenosis of the carotid artery, or stroke or transient ischemic attack at 3 months prior to randomization F) History of aortiti s or immune vasculitis G) Patients in the acute phase of various diseases or with unstable clinical symptoms H) Patients with nerve, muscle and bone diseases, unable to exercise normally I) Serious adverse reactions or significant ECG changes occurred during the exercise endurance test 3. Any other investigator deemed inappropriate to participate in this study.

研究实施时间:

Study execute time:

From 2023-12-20 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-12-29 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

75

Group:

Exercise

Sample size:

干预措施:

运动+药物治疗组

干预措施代码:

Intervention:

Exercise+Medicine

Intervention code:

组别:

对照组

样本量:

75

Group:

Control group

Sample size:

干预措施:

常规药物治疗

干预措施代码:

Intervention:

Routine Medicine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

解放军总医院 

单位级别:

三甲 

Institution
hospital:

Chinese PLA General Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学齐鲁医院 

单位级别:

三甲 

Institution
hospital:

Qilu Hospital of Shangdong University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China

Province:

Henan

City:

单位(医院):

阜外华中心血管病医院 

单位级别:

三甲 

Institution
hospital:

Fuwai Centrak China Cardiovascular Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

中南大学湘雅医院 

单位级别:

三甲 

Institution
hospital:

Xiangya Hospital Central South University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脉搏波传导速度

指标类型:

主要指标

Outcome:

Pulse wave velocity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

踝臂指数

指标类型:

次要指标

Outcome:

ABI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心血管住院治疗

指标类型:

次要指标

Outcome:

Cardiovascular hospitalization

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心肌梗死

指标类型:

次要指标

Outcome:

MI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

短暂性脑缺血发作或卒中

指标类型:

次要指标

Outcome:

TIA/STROKE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全因死亡

指标类型:

次要指标

Outcome:

all cause death

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

峰值摄氧量

指标类型:

次要指标

Outcome:

PVO2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

颈动脉内中膜厚度

指标类型:

次要指标

Outcome:

IMT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素6

指标类型:

次要指标

Outcome:

IL-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

CRP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

life quality

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机信封法

Randomization Procedure (please state who generates the random number sequence and by what method):

Dynamic minimization method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

none

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本课题采用病例记录表进行数据采集,由研究者进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

In this subject, standard data collection and management system include a CRF and an electronic data capture, and the data management is carried out by the researcher.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-12-22 11:16:50